RCKT LAWSUIT ALERT: The Gross Law Firm Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. Stock Price Impact - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share, marking a decline of approximately 37% in just one trading day [3]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action, with a deadline of August 11, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [5].